Article Versions Notes

Tsai J-S, Wei S-H, Chen C-W, Yang S-C, Tseng Y-L, Su P-L, Lin C-C, Su W-C. Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. Pharmaceuticals. 2022; 15(11):1407. https://doi.org/10.3390/ph15111407

Tsai, Jeng-Shiuan, Sheng-Huan Wei, Chian-Wei Chen, Szu-Chun Yang, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin, and Wu-Chou Su. 2022. "Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio" Pharmaceuticals 15, no. 11: 1407. https://doi.org/10.3390/ph15111407

Tsai, J.-S., Wei, S.-H., Chen, C.-W., Yang, S.-C., Tseng, Y.-L., Su, P.-L., Lin, C.-C., & Su, W.-C. (2022). Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. Pharmaceuticals, 15(11), 1407. https://doi.org/10.3390/ph15111407